BofA warns Fed risks policy mistake with early rate cuts
Michael Blisko, a director at Strawberry Fields REIT, Inc. (NASDAQ:STRW), recently made a significant acquisition of the company's common stock. According to a Form 4 filing with the Securities and Exchange Commission, Blisko purchased 10,000 shares on April 8, 2025, at a price of $9.25 per share, totaling $92,500. The purchase comes as InvestingPro analysis indicates the stock is currently undervalued, with the company maintaining a healthy 5.13% dividend yield and strong financial health metrics. Following this transaction, Blisko's indirect ownership, through Blisko Enterprises Limited, stands at 314,582 shares. This move highlights Blisko's continued investment in the real estate investment trust, which specializes in healthcare facilities. The company has raised its dividend for three consecutive years, with InvestingPro data revealing eight additional key insights about STRW's growth potential and valuation metrics.
In other recent news, Strawberry Fields REIT has made significant strides in expanding its portfolio. The company recently acquired properties valued at $115 million, which is expected to boost its quarterly earnings from $0.28 per share to $0.35 per share. This development follows a capital raise through a marketed offering in December 2024. Compass Point has initiated coverage on Strawberry Fields REIT with a Buy rating and set a price target of $14.00. The firm emphasizes the company's strategic focus on healthcare properties leased to operators in skilled nursing and acute care sectors. This focus is seen as a potential advantage due to the aging baby boomer population. The company's co-founders, Moishe Gubin and Michael Blisko, maintain significant ownership, holding around 11% of common shares and 86% of outstanding Operating Partnership units. Strawberry Fields REIT primarily leases to for-profit operators that receive reimbursements from Medicare, Medicaid, and private sources.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.